skip to the content

AVAiL: no new safety signals for Avastin combined with cisplatin/gemcitabine

AVAiL: Avastin has a favourable and well-established safety profile, consistent with previous trials

 
AVAiL: severe AEs

Summary of severe (grade ≥3) AEs of special interest11

Reprinted with the kind permission of the author.

  • The safety of Avastin in the AVAiL trial was comparable to that observed in ECOG 4599.5,8,11
  • There was no evidence that thromboembolic events, GI perforations, cardiac disorders or wound-healing complications were increased with Avastin-based therapy versus chemotherapy alone.
  • Grade ≥3 haemoptysis occurred in 0.9%, 0.9% and 0.3% of patients in the 7.5mg/kg Avastin, 15mg/kg Avastin and placebo arms, respectively.
  • The overall incidence of grade ≥3 AEs was comparable across all arms.
  • Clinically significant events were infrequent.
 

Next

Back